June 5, 2014European Journal of Heart Failure
Growth-Differentiation Factor 15 and Osteoprotegerin in Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Biomarker Substudy of the IABP-SHOCK II-Trial
Why the study?
Do elevated levels of GDF-15 and OPG predict 30-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock?
Population
190 patients with cardiogenic shock complicating acute myocardial infarction undergoing early…
Comparison
GDF-15 and OPG serum levels greater than the… vs GDF-15 and OPG serum levels less than or equal…
Design
Cohort
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
May support GDF-15 for risk stratification in AMI shock; leaves open whether it guides therapy or improves outcomes.
Structured PICO
Do elevated levels of GDF-15 and OPG predict 30-day mortality in patients with acute myocardial infarction complicated by cardiogenic shock?
P
Population
190 patients with cardiogenic shock complicating acute myocardial infarction undergoing early revascularization (substudy of the IABP-SHOCK II trial)
I
Intervention
GDF-15 and OPG serum levels greater than the median
C
Comparator
GDF-15 and OPG serum levels less than or equal to the median
O
Outcome
30-day mortalityhard clinical
GDF-15 measured on admission is a significant independent predictor of short-term mortality in patients with acute myocardial infarction complicated by cardiogenic shock.
Cite This Study
Fuernau et al. (2014) studied this question.